Horizon Pharma (HZNP) Receiving Somewhat Positive Media Coverage, Accern Reports
Media stories about Horizon Pharma (NASDAQ:HZNP) have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Horizon Pharma earned a news impact score of 0.19 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.2726793969103 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Horizon Pharma Sees Unusually Large Options Volume (HZNP) (americanbankingnews.com)
- Horizon Pharma (HZNP) Upgraded to “Buy” by Mizuho (americanbankingnews.com)
- Volume Moving the Tape -0.32% For Horizon Pharma Ord (HZNP) – SCY News (scynews.com)
- Worthy Analytical Review for Horizon Pharma plc (NASDAQ:HZNP … – The Oracle Examiner (oracleexaminer.com)
- Horizon Pharma (HZNP) Increases Peak Net Sales Guidance, Announces Rheumatology and Orphan Pipeline … – StreetInsider.com (streetinsider.com)
HZNP has been the subject of several analyst reports. Jefferies Group lifted their price target on shares of Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Stifel Nicolaus reissued a “buy” rating and set a $20.00 price target on shares of Horizon Pharma in a report on Sunday, October 22nd. ValuEngine raised shares of Horizon Pharma from a “hold” rating to a “buy” rating in a report on Monday, October 16th. Mizuho raised shares of Horizon Pharma from a “neutral” rating to a “buy” rating and lifted their price target for the company from $12.00 to $18.00 in a report on Friday. Finally, Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the company’s stock. Horizon Pharma has a consensus rating of “Buy” and an average price target of $19.25.
Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The company had revenue of $271.60 million during the quarter, compared to the consensus estimate of $259.74 million. During the same period in the previous year, the firm posted $0.70 earnings per share. The company’s revenue was up 30.1% on a year-over-year basis. sell-side analysts anticipate that Horizon Pharma will post 0.72 EPS for the current year.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.